{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:18:04Z","timestamp":1769113084192,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Given the high risk of relapse for Philadelphia-negative (Ph-negative) B-cell acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (allo-HCT) is often recommended following first complete remission (CR1) in high-risk patients. However, in the era of measurable residual disease (MRD) testing, allo-HCT may not be indicated for patients with standard-risk disease. Here we review the use of allo-HCT and other consolidative approaches for standard- and high-risk Ph-negative ALL, based on MRD following induction therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Allo-HCT is strongly indicated for patients with high-risk Ph-negative ALL, especially those who are MRD positive at end of induction. Ongoing trials using cellular and immune therapies such as blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T-cell therapies have shown promising results in deepening response and decreasing relapse. Further, these agents have demonstrated overall manageable safety profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The role for allo-HCT following CR1 in patients with standard risk Ph-negative ALL is evolving with advances in therapeutic approaches. MRD is emerging as a critical prognostic factor regardless of treatment strategy, thus questioning the necessity of transplant in MRD-negative patients. With the advances in safety and accessibility of allo-HCT as well as novel therapeutics, overall outcomes in ALL continue to improve.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11899-025-00760-3","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T08:45:09Z","timestamp":1762245909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From MRD To Match: the Role of Allogeneic Hematopoietic Cell Transplant in Philadelphia-Negative B-ALL"],"prefix":"10.1007","volume":"20","author":[{"given":"Jessica","family":"El-Asmar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betty Ky","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"20","key":"760_CR1","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","volume":"22","author":"X Thomas","year":"2004","unstructured":"Thomas X, Boiron J-M, Huguet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075\u201386.","journal-title":"J Clin Oncol"},{"issue":"2","key":"760_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11899-020-00582-5","volume":"15","author":"F El Chaer","year":"2020","unstructured":"El Chaer F, Keng M, Ballen KK. MLL-Rearranged acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2020;15(2):83\u20139.","journal-title":"Curr Hematol Malig Rep"},{"key":"760_CR3","doi-asserted-by":"crossref","unstructured":"K\u00fcnz T, Hauswirth AW, Hetzenauer G, Rudzki J, Nachbaur D, Steiner N. Changing landscape in the treatment of adult acute lymphoblastic leukemia (ALL). Cancers (Basel). 2022;14(17).","DOI":"10.3390\/cancers14174290"},{"issue":"2","key":"760_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/CCO.0b013e32834f5c41","volume":"24","author":"SK Khaled","year":"2012","unstructured":"Khaled SK, Thomas SH, Forman SJ. Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. Curr Opin Oncol. 2012;24(2):182\u201390.","journal-title":"Curr Opin Oncol"},{"issue":"26","key":"760_CR5","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1182\/blood-2015-02-580043","volume":"125","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125(26):3977\u201387.","journal-title":"Blood"},{"issue":"5","key":"760_CR6","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1182\/bloodadvances.2023011661","volume":"8","author":"A Enshaei","year":"2024","unstructured":"Enshaei A, Joy M, Butler E, Kirkwood AA, Messina M, Pavoni C, et al. A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study. Blood Adv. 2024;8(5):1155\u201366.","journal-title":"Blood Adv"},{"issue":"11","key":"760_CR7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.bbmt.2019.08.014","volume":"25","author":"Z DeFilipp","year":"2019","unstructured":"DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, et al. Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 Evidence-Based review from the American society for transplantation and cellular therapy. Biol Blood Marrow Transplant. 2019;25(11):2113\u201323.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"760_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11899-022-00664-6","volume":"17","author":"E Pierce","year":"2022","unstructured":"Pierce E, Mautner B, Mort J, Blewett A, Morris A, Keng M, et al. MRD in ALL: optimization and innovations. Curr Hematol Malig Rep. 2022;17(4):69\u201381.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"760_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood.2023023156","volume":"145","author":"N G\u00f6kbuget","year":"2025","unstructured":"G\u00f6kbuget N, Steffen B. How I treat older patients with Ph\/BCR-ABL\u2013negative acute lymphoblastic leukemia. Blood. 2025;145(1):53\u201363.","journal-title":"Blood"},{"issue":"18","key":"760_CR10","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","volume":"113","author":"R Bassan","year":"2009","unstructured":"Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153\u201362.","journal-title":"Blood"},{"issue":"10","key":"760_CR11","doi-asserted-by":"publisher","first-page":"e35872","DOI":"10.1002\/cncr.35872","volume":"131","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Jain N, Litzow MR, Luger SM, Papayannidis C, Ribera J-M, et al. The evolving therapeutic revolution in adult acute lymphoblastic leukemia. Cancer. 2025;131(10):e35872.","journal-title":"Cancer"},{"issue":"3","key":"760_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2353\/jmoldx.2009.080048","volume":"11","author":"AA Morley","year":"2009","unstructured":"Morley AA, Latham S, Brisco MJ, Sykes PJ, Sutton R, Hughes E, et al. Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia. J Mol Diagn. 2009;11(3):201\u201310.","journal-title":"J Mol Diagn"},{"issue":"13","key":"760_CR13","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","volume":"6","author":"NJ Short","year":"2022","unstructured":"Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022;6(13):4006\u201314.","journal-title":"Blood Adv"},{"issue":"12","key":"760_CR14","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","volume":"107","author":"C Saygin","year":"2022","unstructured":"Saygin C, Cannova J, Stock W, Muffly L. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022;107(12):2783\u201393.","journal-title":"Haematologica"},{"issue":"10","key":"760_CR15","doi-asserted-by":"publisher","first-page":"e0163599","DOI":"10.1371\/journal.pone.0163599","volume":"11","author":"M Zhang","year":"2016","unstructured":"Zhang M, Fu H, Lai X, Tan Y, Zheng W, Shi J, et al. Minimal residual disease at first achievement of complete remission predicts outcome in adult patients with Philadelphia Chromosome-Negative acute lymphoblastic leukemia. PLoS ONE. 2016;11(10):e0163599.","journal-title":"PLoS ONE"},{"issue":"10","key":"760_CR16","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","volume":"104","author":"R Bassan","year":"2019","unstructured":"Bassan R, Br\u00fcggemann M, Radcliffe HS, Hartfield E, Kreuzbauer G, Wetten S. A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica. 2019;104(10):2028\u201339.","journal-title":"Haematologica"},{"issue":"15","key":"760_CR17","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"J-M Ribera","year":"2014","unstructured":"Ribera J-M, Oriol A, Morgades M, Montesinos P, Sarr\u00e0 J, Gonz\u00e1lez-Campos J, et al. Treatment of High-Risk Philadelphia Chromosome\u2013Negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15):1595\u2013604.","journal-title":"J Clin Oncol"},{"issue":"14","key":"760_CR18","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1182\/blood.2020007311","volume":"137","author":"J-M Ribera","year":"2021","unstructured":"Ribera J-M, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesc\u00e0 E, et al. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome\u2013negative adult lymphoblastic leukemia. Blood. 2021;137(14):1879\u201394.","journal-title":"Blood"},{"issue":"10","key":"760_CR19","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1080\/10428194.2024.2364043","volume":"65","author":"NJ Short","year":"2024","unstructured":"Short NJ, Kantarjian H, Jabbour E. Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens. Leuk Lymphoma. 2024;65(10):1405\u201317.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"760_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13045-020-00879-1","volume":"13","author":"M Lv","year":"2020","unstructured":"Lv M, Jiang Q, Zhou DB, Hu Y, Liu DH, Wu DP, et al. Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. J Hematol Oncol. 2020;13(1):52.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"760_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","volume":"39","author":"C Peters","year":"2021","unstructured":"Peters C, Dalle J-H, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: A Multinational, Randomized, noninferiority phase III study. J Clin Oncol. 2021;39(4):295\u2013307.","journal-title":"J Clin Oncol"},{"issue":"6","key":"760_CR22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/sj.bmt.1704198","volume":"32","author":"N Bunin","year":"2003","unstructured":"Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of Busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: A pediatric blood and marrow transplant consortium study. Bone Marrow Transplant. 2003;32(6):543\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"760_CR23","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","volume":"125","author":"N Dh\u00e9din","year":"2015","unstructured":"Dh\u00e9din N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125(16):2486\u201396.","journal-title":"Blood"},{"issue":"6","key":"760_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","volume":"27","author":"F Huguet","year":"2009","unstructured":"Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911\u20138.","journal-title":"J Clin Oncol"},{"issue":"14","key":"760_CR25","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1200\/JCO.21.01766","volume":"40","author":"AS Advani","year":"2022","unstructured":"Advani AS, Moseley A, O\u2019Dwyer KM, Wood BL, Fang M, Wieduwilt MJ, et al. SWOG 1318: A phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia Chromosome-Negative B-Cell acute lymphoblastic leukemia. J Clin Oncol. 2022;40(14):1574\u201382.","journal-title":"J Clin Oncol"},{"issue":"12","key":"760_CR26","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","volume":"9","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022;9(12):e878\u201385.","journal-title":"Lancet Haematol"},{"issue":"1","key":"760_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41408-024-01179-4","volume":"14","author":"EJ Jabbour","year":"2024","unstructured":"Jabbour EJ, Kantarjian HM, Goekbuget N, Shah BD, Chiaretti S, Park JH, et al. Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab. Blood Cancer J. 2024;14(1):203.","journal-title":"Blood Cancer J"},{"issue":"4","key":"760_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-Negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391(4):320\u201333.","journal-title":"N Engl J Med"},{"key":"760_CR29","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1182\/blood-2023-174973","volume":"142","author":"S Chiaretti","year":"2023","unstructured":"Chiaretti S, Della Starza I, Santoro A, Spinelli O, Elia L, De Propris MS, et al. Sequential chemotherapy and blinatumomab to improve minimal residual disease in adult Ph- B-Lineage acute lymphoblastic Leukemia. Final results of the phase II Gimema LAL2317 trial. Blood. 2023;142:826.","journal-title":"Blood"},{"key":"760_CR30","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/01.HS9.0000844352.62588.a4","volume":"6","author":"A Rijneveld","year":"2022","unstructured":"Rijneveld A, Gradowska P, Bellido M, de Weerdt O, Gadisseur A, Deeren D, et al. P366: BLINATUMOMAB ADDED TO PREPHASE AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED PRECURSOR B-ALL IN ADULTS. A PHASE II HOVON TRIAL. HemaSphere. 2022;6:266\u20137.","journal-title":"HemaSphere"},{"issue":"11","key":"760_CR31","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","volume":"61","author":"N G\u00f6kbuget","year":"2020","unstructured":"G\u00f6kbuget N, Zugmaier G, Dombret H, Stein A, Bonifacio M, Graux C, et al. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(11):2665\u201373.","journal-title":"Leuk Lymphoma"},{"key":"760_CR32","doi-asserted-by":"crossref","unstructured":"Kantarjian Hagop M, DeAngelo Daniel J, Stelljes M, Martinelli G, Liedtke M, Stock W et al. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 375(8):740\u201353.","DOI":"10.1056\/NEJMoa1509277"},{"issue":"3","key":"760_CR33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.23.00546","volume":"42","author":"M Stelljes","year":"2024","unstructured":"Stelljes M, Raffel S, Alakel N, W\u00e4sch R, Kondakci M, Scholl S, et al. Inotuzumab Ozogamicin as induction therapy for patients older than 55 years with Philadelphia Chromosome\u2013Negative B-Precursor ALL. J Clin Oncol. 2024;42(3):273\u201382.","journal-title":"J Clin Oncol"},{"issue":"36","key":"760_CR34","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1200\/JCO.24.00490","volume":"42","author":"P Chevallier","year":"2024","unstructured":"Chevallier P, Leguay T, Delord M, Salek C, Kim R, Huguet F, et al. Inotuzumab Ozogamicin and Low-Intensity chemotherapy in older patients with newly diagnosed CD22\u2009+\u2009Philadelphia Chromosome\u2013Negative B-Cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2024;42(36):4327\u201341.","journal-title":"J Clin Oncol"},{"issue":"6","key":"760_CR35","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023;10(6):e433\u201344.","journal-title":"Lancet Haematol"},{"issue":"5","key":"760_CR36","first-page":"1385","volume":"109","author":"S Kayser","year":"2024","unstructured":"Kayser S, Sartor C, Giglio F, Bruno A, Webster J, Chiusolo P, et al. Impact of inotuzumab Ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome\/venous occlusive disease. Haematologica. 2024;109(5):1385\u201392.","journal-title":"Haematologica"},{"issue":"1","key":"760_CR37","doi-asserted-by":"publisher","first-page":"2378543","DOI":"10.1080\/21645515.2024.2378543","volume":"20","author":"D Goyco Vera","year":"2024","unstructured":"Goyco Vera D, Waghela H, Nuh M, Pan J, Lulla P. Approved CAR-T therapies have reproducible efficacy and safety in clinical practice. Hum Vaccin Immunother. 2024;20(1):2378543.","journal-title":"Hum Vaccin Immunother"},{"issue":"23","key":"760_CR38","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu Karamjeet S, Tholouli E, Logan Aaron C, Shaughnessy P, Barba P, et al. Obecabtagene autoleucel in adults with B-Cell acute lymphoblastic leukemia. N Engl J Med. 2024;391(23):2219\u201330.","journal-title":"N Engl J Med"},{"issue":"5","key":"760_CR39","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","volume":"39","author":"BD Shah","year":"2025","unstructured":"Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, et al. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with Brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025;39(5):1058\u201368.","journal-title":"Leukemia"},{"issue":"10","key":"760_CR40","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/oncolo\/oyac163","volume":"27","author":"N Bouchkouj","year":"2022","unstructured":"Bouchkouj N, Lin X, Wang X, Przepiorka D, Xu Z, Purohit-Sheth T, et al. FDA approval summary: Brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-Cell precursor acute lymphoblastic leukemia. Oncologist. 2022;27(10):892\u20139.","journal-title":"Oncologist"},{"issue":"5","key":"760_CR41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"10","key":"760_CR42","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504\u20136.","journal-title":"Nat Med"},{"issue":"1","key":"760_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/hematology.2021000225","volume":"2021","author":"NV Frey","year":"2021","unstructured":"Frey NV, Relapsed ALL. CAR T vs transplant vs novel therapies. Hematol Am Soc Hematol Educ Program. 2021;2021(1):1\u20136.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"22","key":"760_CR44","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-Cell therapies for cancer: A translational science review. JAMA. 2024;332(22):1924\u201335.","journal-title":"JAMA"},{"issue":"6","key":"760_CR45","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41375-020-01056-6","volume":"35","author":"C Zhang","year":"2021","unstructured":"Zhang C, Wang XQ, Zhang RL, Liu F, Wang Y, Yan ZL, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia. 2021;35(6):1563\u201370.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"760_CR46","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1182\/blood-2023-184740","volume":"142","author":"J Feng","year":"2023","unstructured":"Feng J, Huang H. A multicenter study of CAR-T cell therapy for relapse of B-ALL post allogeneic stem cell transplantation. Blood. 2023;142(Supplement 1):3485.","journal-title":"Blood"},{"issue":"15","key":"760_CR47","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Long-Term Follow-Up of CD19-CAR T-Cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021;39(15):1650\u20139.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s11899-025-00766-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000}}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00760-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-025-00760-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00760-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:03:24Z","timestamp":1769051004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-025-00760-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["760"],"URL":"https:\/\/doi.org\/10.1007\/s11899-025-00760-3","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The original published version of this article unfortunately contained a mistake. Tables 1-3 were inadvertently omitted and should have been included. The online version has now been updated to include these missing tables.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11899-025-00766-x","URL":"https:\/\/doi.org\/10.1007\/s11899-025-00766-x","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"18"}}